State Street Corp Avadel Pharmaceuticals PLC Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$12.55 - $17.22 $66,038 - $90,611	-5,262 Reduced 12.5%	36,844 $622,000
Q4 2023 Feb 14, 2024	BUY	$9.64 - $14.59 $113,752 - $172,162	11,800 Added 38.94%	42,106 $594,000
Q3 2023 Nov 14, 2023	BUY	$10.3 - $15.99 $76,220 - $118,326	7,400 Added 32.31%	30,306 $312,000
Q2 2023 Aug 14, 2023	SELL	$8.48 - $16.48 $606,260 - $1.18 Million	-71,493 Reduced 75.73%	22,906 $377,000
Q1 2023 May 15, 2023	BUY	$6.41 - $9.95 $65,933 - $102,345	10,286 Added 12.23%	94,399 $864,000
Q4 2022 Feb 14, 2023	SELL	$5.02 - $10.0 $210,950 - $420,220	-42,022 Reduced 33.32%	84,113 $602,000
Q3 2022 Nov 15, 2022	SELL	$2.57 - $7.31 $117,749 - $334,922	-45,817 Reduced 26.65%	126,135 $632,000
Q2 2022 Aug 15, 2022	SELL	$1.07 - $6.95 $36,210 - $235,201	-33,842 Reduced 16.44%	171,952 $420,000
Q1 2022 May 16, 2022	BUY	$5.46 - $8.29 $88,877 - $134,944	16,278 Added 8.59%	205,794 $1.41 Million
Q4 2021 Feb 14, 2022	BUY	$7.34 - $11.18 $181,532 - $276,503	24,732 Added 15.01%	189,516 $1.53 Million
Q3 2021 Nov 15, 2021	BUY	$6.49 - $9.91 $164,326 - $250,921	25,320 Added 18.16%	164,784 $1.62 Million
Q2 2021 Aug 16, 2021	BUY	$6.73 - $9.05 $126,328 - $169,877	18,771 Added 15.55%	139,464 $939,000
Q1 2021 May 17, 2021	BUY	$6.61 - $10.07 $180,961 - $275,686	27,377 Added 29.34%	120,693 $1.09 Million
Q4 2020 Feb 16, 2021	BUY	$5.03 - $7.95 $52,905 - $83,618	10,518 Added 12.7%	93,316 $624,000
Q3 2020 Nov 10, 2020	BUY	$5.02 - $8.98 $322,565 - $577,018	64,256 Added 346.54%	82,798 $417,000
Q2 2020 Aug 14, 2020	BUY	$7.25 - $11.75 $134,429 - $217,868	18,542 New	18,542 $150,000

Others Institutions Holding AVDL

# of Institutions

Shares Held

1.07M

Call Options Held

Put Options Held

View Full List

About AVADEL PHARMACEUTICALS PLC

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

More about AVDL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account